Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image: Bayer’s planned Perfuse Therapeutics acquisition highlights the intensifying race to develop next-generation ophthalmology treatments beyond Eylea, with PER-001 adding a potential new pathway for glaucoma and diabetic retinopathy innovation.
Pharma & Biotech

Inside Bayer’s $2.45bn push to defend its ophthalmology franchise

Eylea is under pressure. Bayer’s $2.45bn Perfuse bet tests whether PER-001 can carry its next ophthalmology growth story.

Read More
Representative image: A biotech laboratory scene showing injectable biologic formulation work, reflecting how the Halozyme Therapeutics and Oruka Therapeutics Hypercon agreement could shape the next phase of long-acting psoriasis drug delivery.
Pharma & Biotech

Why Halozyme’s Hypercon deal with Oruka could matter beyond one psoriasis antibody

Psoriasis biologics are getting longer acting. Halozyme and Oruka now face the harder test of making high-dose therapy practical.

Read More
Representative image: Angelini Pharma’s $4.1 billion Catalyst Pharmaceuticals acquisition highlights the growing race for rare disease and neurology assets, with Firdapse, Agamree and U.S. commercial scale at the center of the deal.
Pharma & Biotech

Angelini Pharma bets $4.1bn on rare neurology scale with Catalyst Pharmaceuticals

Angelini gains U.S. rare disease scale. Catalyst gets certainty, but Firdapse concentration keeps the real test ahead.

Read More
Representative image of a modern U.S. pharmaceutical manufacturing campus, highlighting how Eli Lilly’s $4.5 billion Indiana expansion could strengthen domestic drug production capacity for obesity, diabetes and advanced genetic medicines.
Pharma & Biotech

Could Eli Lilly’s $4.5bn Indiana investment widen its lead in obesity and advanced therapies?

Obesity drug demand is outrunning pharma capacity. Eli Lilly’s Indiana bet shows manufacturing is now a strategic moat.

Read More
Representative image: GSK’s $1 billion SiranBio deal highlights how oligonucleotide therapies such as SA030 could open a new front in metabolic disease research by targeting visceral fat biology beyond conventional obesity drugs.
Pharma & Biotech

GSK’s $1bn SiranBio pact raises the stakes in extrahepatic siRNA delivery

GLP-1 drugs dominate obesity. GSK is betting SiranBio’s SA030 can attack visceral fat risk from a different angle.

Read More
Representative image of AI-powered digital pathology and oncology biomarker analysis, illustrating how Daiichi Sankyo and Waiv’s ADC collaboration could support smarter patient selection in precision cancer drug development.
Pharma & Biotech

Why Daiichi Sankyo’s Waiv collaboration matters for the next phase of ADC oncology trials

ADC trials need sharper patient selection. Daiichi Sankyo’s Waiv deal tests whether AI pathology can find response signals earlier.

Read More
Representative image: Novo Nordisk’s Wegovy pill launch in the U.S. obesity drug market is illustrated through unbranded tablets, prescription growth data and healthcare market signals, reflecting rising demand for oral GLP-1 weight-loss treatments.
Pharma & Biotech

Can Novo Nordisk’s Wegovy pill reshape the obesity market before Eli Lilly catches up?

Novo Nordisk has the first-mover pill. Eli Lilly has the growth aura. Oral obesity drugs are turning access into the next GLP-1 battleground.

Read More
Hammes project completion gives Boca Grande a bigger local healthcare platform
Pharma & Biotech

Can Hammes’ Boca Grande project reshape healthcare access on Gasparilla Island?

Island healthcare has a scale problem. Boca Grande Health Clinic’s new facility shows how local care access is being rebuilt closer to patients.

Read More
Representative image: Mabwell’s 9MW5211 FDA clearance highlights growing clinical interest in first-in-class antibody therapies for inflammatory bowel disease, as biotech developers target pathogenic immune cells to reshape autoimmune disease treatment.
Pharma & Biotech

Mabwell’s 9MW5211 gets FDA clearance, but can a first-in-class autoimmune antibody break through?

Mabwell has FDA clearance for 9MW5211. The bigger test is whether a first-in-class autoimmune antibody can prove durable remission.

Read More
Pharma & Biotech

Can Plus Therapeutics Inc. turn REYOBIQ into a differentiated platform for difficult-to-treat CNS cancers?

Can REYOBIQ change CNS cancer treatment? Discover why Plus Therapeutics Inc.’s latest leptomeningeal metastases data is drawing attention.

Read More